Incident Cervical HPV Infections in Young Women: Transition Probabilities for CIN and Infection Clearance

被引:99
作者
Insinga, Ralph P. [1 ]
Perez, Gonzalo [2 ]
Wheeler, Cosette M. [3 ,4 ]
Koutsky, Laura A. [5 ]
Garland, Suzanne M. [6 ,7 ]
Leodolter, Sepp [8 ]
Joura, Elmar A. [8 ]
Ferris, Daron G. [9 ,10 ]
Steben, Marc [11 ]
Hernandez-Avila, Mauricio [12 ]
Brown, Darron R. [13 ]
Elbasha, Elamin [1 ]
Munoz, Nubia [14 ]
Paavonen, Jorma [15 ]
Haupt, Richard M.
机构
[1] Merck & Co Inc, Merck Res Labs, N Wales, PA 19454 USA
[2] Univ Rosario, Bogota, Colombia
[3] Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA
[4] Univ New Mexico, Hlth Sci Ctr, Dept Gynecol, Albuquerque, NM 87131 USA
[5] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[6] Univ Melbourne, Microbiol & Infect Dis Dept, Royal Womens Hosp, Melbourne, Vic, Australia
[7] Univ Melbourne, Dept Obstet & Gynecol, Melbourne, Vic, Australia
[8] Med Univ Vienna, Dept Gynecol & Obstet, Vienna, Austria
[9] Med Coll Georgia, Dept Family Med, Augusta, GA 30912 USA
[10] Med Coll Georgia, Dept Obstet & Gynecol, Augusta, GA 30912 USA
[11] Inst Natl Sante Publ Quebec, Direct Risques Biol & Sante Travail, Montreal, PQ, Canada
[12] Minist Hlth, Mexico City, DF, Mexico
[13] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN USA
[14] Natl Canc Inst, Bogota, Colombia
[15] Univ Cent Hosp, Dept Obstet & Gynecol, Helsinki, Finland
关键词
HUMAN-PAPILLOMAVIRUS TYPES; INTRAEPITHELIAL NEOPLASIA GRADE-2; AGED; 16-26; YEARS; PARTICLE VACCINE; UNITED-STATES; CANCER; LESIONS; DURATION; DISEASE; TYPE-16;
D O I
10.1158/1055-9965.EPI-10-0791
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background: We describe transition probabilities for incident human papillomavirus (HPV) 16/18/31/33/35/45/52/58/59 infections and cervical intraepithelial neoplasia (CIN) 1 lesions. Methods: Women ages 16 to 23 years underwent cytology and cervical swab PCR testing for HPV at approximately 6-month intervals for up to 4 years in the placebo arm of an HPV vaccine trial. The cumulative proportion of incident HPV infections with diagnosed CIN, clearing (infection undetectable), or persisting without CIN, were estimated. Results: Most incident infections cleared, without detection of CIN, ranging at 36 months from 66.9% for HPV31 to 91.1% for HPV59. There was little variation in the 36-month proportion of incident HPV16, 18, and 31 infections followed by a CIN1 lesion positive for the relevant HPV type (range 16.7%-18.6%), with lower risks for HPV59 (6.4%) and HPV33 (2.9%). Thirty-six-month transition probabilities for CIN2 ranged across types from 2.2% to 9.1%; however, the number of events was generally too small for statistically significant differences to be seen across types for this endpoint, or CIN3. Conclusions: Some incident HPV types appear more likely to result in diagnosed CIN1 than others. The relative predominance of HPV16, vis-a-vis some other high-risk HPV types (e. g., HPV33) in prevalent CIN2/3, appears more directly associated with relatively greater frequency of incident HPV16 infections within the population, than a higher risk of infection progression to CIN2/3. Impact: Nearly all incident HPV infections either manifest as detectable CIN or become undetectable within 36 months. Some HPV types (e. g., 16 and 33) appear to have similar risk of CIN2/3 despite widely varied incidence. Cancer Epidemiol Biomarkers Prev; 20(2); 287-96. (C)2011 AACR.
引用
收藏
页码:287 / 296
页数:10
相关论文
共 42 条
[1]
Competing risks as a multi-state model [J].
Andersen, PK ;
Abildstrom, SZ ;
Rosthoj, S .
STATISTICAL METHODS IN MEDICAL RESEARCH, 2002, 11 (02) :203-215
[2]
[Anonymous], 1993, An introduction to the bootstrap
[3]
Bergeron C, 2006, Gynecol Obstet Fertil, V34, P1036, DOI 10.1016/j.gyobfe.2006.09.005
[4]
The epidemiology of human papillomavirus infection and cervical cancer [J].
Bosch, F. Xavier ;
de Sanjose, Silvia .
DISEASE MARKERS, 2007, 23 (04) :213-227
[5]
Aberrant expression of VEGF-C is related to grade of cervical intraepithelial neoplasia (CIN) and high risk HPV, but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer [J].
Branca, M ;
Giorgi, C ;
Santini, D ;
Di Bonito, L ;
Ciotti, M ;
Benedetto, A ;
Paba, P ;
Costa, S ;
Bonifacio, D ;
Di Bonito, P ;
Accardi, L ;
Favalli, C ;
Syrjänen, K .
JOURNAL OF CLINICAL PATHOLOGY, 2006, 59 (01) :40-47
[6]
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years [J].
Brown, Darron R. ;
Kjaer, Susanne K. ;
Sigurdsson, Kristjan ;
Iversen, Ole-Erik ;
Hernandez-Avila, Mauricio ;
Wheeler, Cosette M. ;
Perez, Gonzalo ;
Koutsky, Laura A. ;
Tay, Eng Hseon ;
Garcia, Patricia ;
Ault, Kevin A. ;
Garland, Suzanne M. ;
Leodolter, Sepp ;
Olsson, Sven-Eric ;
Tang, Grace W. K. ;
Ferris, Daron G. ;
Paavonen, Jorma ;
Steben, Marc ;
Bosch, F. Xavier ;
Dillner, Joakim ;
Joura, Elmar A. ;
Kurman, Robert J. ;
Majewski, Slawomir ;
Munoz, Nubia ;
Myers, Evan R. ;
Villa, Luisa L. ;
Taddeo, Frank J. ;
Roberts, Christine ;
Tadesse, Amha ;
Bryan, Janine ;
Lupinacci, Lisa C. ;
Giacoletti, Katherine E. D. ;
Sings, Heather L. ;
James, Margaret ;
Hesley, Teresa M. ;
Barra, Eliav .
JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (07) :926-935
[7]
A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women [J].
Brown, DR ;
Shew, ML ;
Qadadri, B ;
Neptune, N ;
Vargas, M ;
Tu, WZ ;
Juliar, BE ;
Breen, TE ;
Fortenberry, JD .
JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (02) :182-192
[8]
Epidemiology and Costs of Screening and Management of Precancerous Lesions of the Cervix in Spain [J].
Castellsague, Xavier ;
Remy, Vanessa ;
Puig-Tintore, Luis M. ;
Sainz de la Cuesta, Ricardo ;
Gonzalez-Rojas, Nuria ;
Cohet, Catherine .
JOURNAL OF LOWER GENITAL TRACT DISEASE, 2009, 13 (01) :38-45
[9]
Human papillomavirus genotype distribution in low-grade cervical lesions: Comparison by geographic region and with cervical cancer. [J].
Clifford, GM ;
Rana, RK ;
Franceschi, S ;
Smith, JS ;
Gough, G ;
Pimenta, JM .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (05) :1157-1164
[10]
Cruickshank ME, 2002, BJOG-INT J OBSTET GY, V109, P579, DOI 10.1016/S1470-0328(02)01554-9